Rice (Oryza sativa L.) features a unique inflorescence organ known as the spikelet, comprising floret, lemma/palea, sterile lemmas, and rudimentary glumes, of which the molecular regulation underlying sterile lemma identity remains elusive. Here, we isolated the G1 locus for sterile lemma specification using an F2 population developed by crossing between Nipponbare and LG7, a variety with a lemma-like-sterile lemma (lsl). An SNP (+323 G/A) in G1 alleles causes a serine to asparagine (S108N) substitution, leading to the lsl phenotype. Mechanistically, we found that G1 transactivates the expressions of both OsMADS34 and TGW2, two genes known to regulate sterile lemma identity and grain size, through binding to the YACTGTW and CArG-box motifs within their promoters, respectively. Subsequently, we reveal that the transactivation activity of G1NIP (allele from Nipponbare) is further enhanced through interactions with either OsMADS34 or TGW2. Furthermore, we demonstrated that G1 specifies sterile lemma identity via OsMADS34 and controls grain size through TGW2. Our results reveal two transcriptional circuits (G1-OsMADS34 and G1-TGW2) that are crucial for determining sterile lemma identity and grain size of rice, providing insights into genetic improvement for breeding programs.
{"title":"Dual Transcriptional Circuits: G1-OsMADS34 and G1-TGW2 Cooperatively Regulate Sterile Lemma Identity and Grain Size in Rice.","authors":"Xuemei Qin, Ping Gan, Jinliang Sun, Di Wu, Ru Li, Tianmin Ouyang, Kaichong Teng, Weijian Cen, Baoxiang Qin, Fang Liu, Rongbai Li, Jijing Luo","doi":"10.1111/pce.70364","DOIUrl":"10.1111/pce.70364","url":null,"abstract":"<p><p>Rice (Oryza sativa L.) features a unique inflorescence organ known as the spikelet, comprising floret, lemma/palea, sterile lemmas, and rudimentary glumes, of which the molecular regulation underlying sterile lemma identity remains elusive. Here, we isolated the G1 locus for sterile lemma specification using an F<sub>2</sub> population developed by crossing between Nipponbare and LG7, a variety with a lemma-like-sterile lemma (lsl). An SNP (+323 G/A) in G1 alleles causes a serine to asparagine (S108N) substitution, leading to the lsl phenotype. Mechanistically, we found that G1 transactivates the expressions of both OsMADS34 and TGW2, two genes known to regulate sterile lemma identity and grain size, through binding to the YACTGTW and CArG-box motifs within their promoters, respectively. Subsequently, we reveal that the transactivation activity of G1<sup>NIP</sup> (allele from Nipponbare) is further enhanced through interactions with either OsMADS34 or TGW2. Furthermore, we demonstrated that G1 specifies sterile lemma identity via OsMADS34 and controls grain size through TGW2. Our results reveal two transcriptional circuits (G1-OsMADS34 and G1-TGW2) that are crucial for determining sterile lemma identity and grain size of rice, providing insights into genetic improvement for breeding programs.</p>","PeriodicalId":222,"journal":{"name":"Plant, Cell & Environment","volume":" ","pages":"2008-2023"},"PeriodicalIF":6.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145898901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-04-01Epub Date: 2026-01-14DOI: 10.1111/joim.70065
{"title":"Correction to \"Soluble urokinase plasminogen activator receptor and interleukin-6 improve prediction of all-cause mortality and major adverse cardiovascular events in Type 1 diabetes\".","authors":"","doi":"10.1111/joim.70065","DOIUrl":"10.1111/joim.70065","url":null,"abstract":"","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":" ","pages":"534-536"},"PeriodicalIF":9.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145984289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-04-01Epub Date: 2026-02-05DOI: 10.1111/joim.70071
Oumarou Nabi, Jonas Spaak, Göran Bergström, Gunnar Engström, Carl Johan Östgren, Andrei Malinovschi, Joel Kullberg, Anders Blomberg, Tomas Jernberg, Daniel P Andersson, Hannes Hagström
Background and aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally, but its prevalence and severity remain poorly characterized in the general population. Our aim was to estimate the prevalence of MASLD and the risk of advanced fibrosis in a large Swedish general population cohort.
Methods: From the Swedish CArdioPulmonary bioImage Study (SCAPIS) cohort, we analyzed 27,763 participants aged 50-64 years who underwent extensive clinical characterization. MASLD was defined as <48 HU on non-contrast liver computed tomography (CT) imaging. The risk for advanced fibrosis was assessed using the dynamic aspartate aminotransferase (AST)/alanine transaminase (ALT) ratio.
Results: MASLD was present in 18.1% of participants and was more common in men than women (25.5% vs. 11.2%). Prevalence increased with cardiometabolic burden: from 7.0% among those without obesity, hypertension, or Type 2 diabetes mellitus (T2DM) to 70.2% among those with all three conditions. MASLD risk was elevated in individuals with obesity alone (adjusted odds ratio [aOR] 5.56; 95% CI = 4.89-6.31), T2DM alone (aOR = 2.66; 95% CI = 2.13-3.33), or hypertension alone (aOR = 1.78; 95% CI = 1.59-1.99). The combination of all three conferred the highest risk (aOR = 17.1; 95% CI = 14.0-20.9). Among persons with MASLD, 24.8% were classified as at risk for advanced fibrosis. Fibrosis risk was independently associated with hypertension (aOR = 1.44; 95% CI = 1.24-1.66), T2DM (aOR = 1.24; 95% CI = 1.06-1.46), male sex (aOR = 1.20; 95% CI = 1.02-1.42), and alcohol consumption (aOR per gram/day = 1.02; 95% CI = 1.01-1.03).
Conclusions: In Sweden, almost one in five middle-aged adults is affected by MASLD, with a quarter of cases at risk of advanced fibrosis. Male sex, obesity, T2DM, and hypertension are important predictors of the prevalence and severity of MASLD.
背景和目的:代谢功能障碍相关脂肪变性肝病(MASLD)是全球最常见的慢性肝病,但其患病率和严重程度在普通人群中仍不清楚。我们的目的是在一个大型瑞典普通人群队列中估计MASLD的患病率和晚期纤维化的风险。方法:来自瑞典心肺生物图像研究(SCAPIS)队列,我们分析了27,763名年龄在50-64岁的参与者,他们接受了广泛的临床特征。结果:18.1%的参与者存在MASLD,男性比女性更常见(25.5%比11.2%)。患病率随着心脏代谢负担的增加而增加:在没有肥胖、高血压或2型糖尿病(T2DM)的人群中,患病率从7.0%上升到所有三种情况的人群中的70.2%。单独肥胖(校正优势比[aOR] 5.56; 95% CI = 4.89-6.31)、单独T2DM (aOR = 2.66; 95% CI = 2.13-3.33)或单独高血压(aOR = 1.78; 95% CI = 1.59-1.99)患者的MASLD风险升高。三者联合使用的风险最高(aOR = 17.1; 95% CI = 14.0-20.9)。在MASLD患者中,24.8%被归类为晚期纤维化风险。纤维化风险与高血压(aOR = 1.44, 95% CI = 1.24-1.66)、T2DM (aOR = 1.24, 95% CI = 1.06-1.46)、男性(aOR = 1.20, 95% CI = 1.02-1.42)和饮酒(aOR / g /day = 1.02, 95% CI = 1.01-1.03)独立相关。结论:在瑞典,几乎五分之一的中年人受到MASLD的影响,其中四分之一的病例有晚期纤维化的风险。男性、肥胖、2型糖尿病和高血压是MASLD患病率和严重程度的重要预测因素。
{"title":"Prevalence and risk factors for metabolic dysfunction-associated steatotic liver disease in Sweden: Insights from the SCAPIS cohort.","authors":"Oumarou Nabi, Jonas Spaak, Göran Bergström, Gunnar Engström, Carl Johan Östgren, Andrei Malinovschi, Joel Kullberg, Anders Blomberg, Tomas Jernberg, Daniel P Andersson, Hannes Hagström","doi":"10.1111/joim.70071","DOIUrl":"10.1111/joim.70071","url":null,"abstract":"<p><strong>Background and aims: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally, but its prevalence and severity remain poorly characterized in the general population. Our aim was to estimate the prevalence of MASLD and the risk of advanced fibrosis in a large Swedish general population cohort.</p><p><strong>Methods: </strong>From the Swedish CArdioPulmonary bioImage Study (SCAPIS) cohort, we analyzed 27,763 participants aged 50-64 years who underwent extensive clinical characterization. MASLD was defined as <48 HU on non-contrast liver computed tomography (CT) imaging. The risk for advanced fibrosis was assessed using the dynamic aspartate aminotransferase (AST)/alanine transaminase (ALT) ratio.</p><p><strong>Results: </strong>MASLD was present in 18.1% of participants and was more common in men than women (25.5% vs. 11.2%). Prevalence increased with cardiometabolic burden: from 7.0% among those without obesity, hypertension, or Type 2 diabetes mellitus (T2DM) to 70.2% among those with all three conditions. MASLD risk was elevated in individuals with obesity alone (adjusted odds ratio [aOR] 5.56; 95% CI = 4.89-6.31), T2DM alone (aOR = 2.66; 95% CI = 2.13-3.33), or hypertension alone (aOR = 1.78; 95% CI = 1.59-1.99). The combination of all three conferred the highest risk (aOR = 17.1; 95% CI = 14.0-20.9). Among persons with MASLD, 24.8% were classified as at risk for advanced fibrosis. Fibrosis risk was independently associated with hypertension (aOR = 1.44; 95% CI = 1.24-1.66), T2DM (aOR = 1.24; 95% CI = 1.06-1.46), male sex (aOR = 1.20; 95% CI = 1.02-1.42), and alcohol consumption (aOR per gram/day = 1.02; 95% CI = 1.01-1.03).</p><p><strong>Conclusions: </strong>In Sweden, almost one in five middle-aged adults is affected by MASLD, with a quarter of cases at risk of advanced fibrosis. Male sex, obesity, T2DM, and hypertension are important predictors of the prevalence and severity of MASLD.</p>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":" ","pages":"481-501"},"PeriodicalIF":9.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12950636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146122923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-04-01Epub Date: 2025-11-20DOI: 10.1111/add.70245
Louis Favril, John Strang, Seena Fazel
Background and aims: People who use drugs are overrepresented in the criminal justice system. We aimed to provide a broad synthesis of the epidemiology, harms and interventions related to drug use and drug use disorders among incarcerated adults worldwide, and highlight gaps in evidence and practice.
Methods: In this structured review, we searched PubMed and Web of Science for articles published between 2015 and August 2025. Systematic reviews, meta-analyses and large primary studies with unselected samples were given preference for inclusion.
Results: Four in ten adults who enter prison meet diagnostic criteria for a drug use disorder, a treatable psychiatric condition often underlying the offences that led to their incarceration. Drug use disorders are approximately ten times more prevalent among people in prison compared with the general population, with a higher excess in women. Comorbid mental disorders are common. Around a third of incarcerated individuals report using drugs during imprisonment, which poses a health and safety risk for people both living and working in prisons. Injecting drug use in prison contributes to blood-borne virus transmission. In addition to its strong link with recidivism, drug use is associated with a markedly increased risk of premature mortality after release from prison, particularly from drug-related causes within the first two weeks post-release. Despite robust evidence supporting the effectiveness of prison-based pharmacological (e.g. opioid agonist treatment) and psychosocial (e.g. therapeutic communities) interventions in reducing drug-related harms, there remains a significant treatment gap within prison settings worldwide. Further research is needed to assess the health benefits of harm reduction services in prisons, including needle and syringe programmes. Strategies to facilitate linkage to and retention in post-release services are key to ensure continuity of care and achieve sustainable treatment outcomes.
Conclusion: The high prevalence of drug use and its multiple adverse outcomes among people in prison underscore the need for provision of evidence-based interventions. Expanding and integrating prison-based and post-release interventions to address drug use has the potential to yield both public health and criminal justice benefits.
背景和目的:在刑事司法系统中,吸毒者的比例过高。我们的目的是对全球被监禁成年人中与药物使用和药物使用障碍有关的流行病学、危害和干预措施进行广泛的综合,并强调证据和实践方面的差距。方法:在这篇结构化综述中,我们检索了PubMed和Web of Science在2015年至2025年8月之间发表的文章。系统评价、荟萃分析和未选择样本的大型初步研究优先纳入。结果:十分之四进入监狱的成年人符合药物使用障碍的诊断标准,这是一种可治疗的精神疾病,通常是导致他们入狱的犯罪行为的基础。与一般人群相比,监狱服刑人员中药物使用障碍的发生率大约高出10倍,其中妇女的比例更高。共病性精神障碍很常见。大约三分之一的被监禁者报告在监禁期间吸毒,这对在监狱生活和工作的人构成健康和安全风险。在监狱中注射毒品有助于血液传播的病毒传播。除了与再犯密切相关外,吸毒还与出狱后过早死亡的风险显著增加有关,特别是在出狱后的头两周内因与毒品有关的原因过早死亡。尽管强有力的证据支持基于监狱的药理学(如阿片类激动剂治疗)和社会心理(如治疗社区)干预措施在减少毒品相关危害方面的有效性,但在世界各地的监狱环境中仍然存在重大的治疗差距。需要进一步研究,以评估监狱减少伤害服务,包括针头和注射器方案对健康的益处。促进与释放后服务的联系和保留的战略是确保护理连续性和实现可持续治疗成果的关键。结论:监狱中吸毒的高流行率及其多种不良后果强调了提供循证干预措施的必要性。扩大和整合基于监狱和释放后的干预措施,以解决吸毒问题,有可能带来公共卫生和刑事司法方面的惠益。
{"title":"Drug use among people in prison: A global review of epidemiology, harms and interventions.","authors":"Louis Favril, John Strang, Seena Fazel","doi":"10.1111/add.70245","DOIUrl":"10.1111/add.70245","url":null,"abstract":"<p><strong>Background and aims: </strong>People who use drugs are overrepresented in the criminal justice system. We aimed to provide a broad synthesis of the epidemiology, harms and interventions related to drug use and drug use disorders among incarcerated adults worldwide, and highlight gaps in evidence and practice.</p><p><strong>Methods: </strong>In this structured review, we searched PubMed and Web of Science for articles published between 2015 and August 2025. Systematic reviews, meta-analyses and large primary studies with unselected samples were given preference for inclusion.</p><p><strong>Results: </strong>Four in ten adults who enter prison meet diagnostic criteria for a drug use disorder, a treatable psychiatric condition often underlying the offences that led to their incarceration. Drug use disorders are approximately ten times more prevalent among people in prison compared with the general population, with a higher excess in women. Comorbid mental disorders are common. Around a third of incarcerated individuals report using drugs during imprisonment, which poses a health and safety risk for people both living and working in prisons. Injecting drug use in prison contributes to blood-borne virus transmission. In addition to its strong link with recidivism, drug use is associated with a markedly increased risk of premature mortality after release from prison, particularly from drug-related causes within the first two weeks post-release. Despite robust evidence supporting the effectiveness of prison-based pharmacological (e.g. opioid agonist treatment) and psychosocial (e.g. therapeutic communities) interventions in reducing drug-related harms, there remains a significant treatment gap within prison settings worldwide. Further research is needed to assess the health benefits of harm reduction services in prisons, including needle and syringe programmes. Strategies to facilitate linkage to and retention in post-release services are key to ensure continuity of care and achieve sustainable treatment outcomes.</p><p><strong>Conclusion: </strong>The high prevalence of drug use and its multiple adverse outcomes among people in prison underscore the need for provision of evidence-based interventions. Expanding and integrating prison-based and post-release interventions to address drug use has the potential to yield both public health and criminal justice benefits.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":"749-764"},"PeriodicalIF":5.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12980310/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145562076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-04-01Epub Date: 2025-11-21DOI: 10.1111/add.70249
Karin Pleym, Elise Sverre, Harald Weedon-Fekjær, Mohpal Singh Kahlon, Marie Stugaard, Einar Husebye, Serena Tonstad, Toril Dammen, John Munkhaugen
<p><strong>Background and aims: </strong>Evidence for motivational interviewing for smoking cessation is weak, with limited data on long-term abstinence rates. This trial aimed to evaluate the effect of in-hospital motivational interviewing-based smoking cessation counselling combined with proactive referral to community-based follow-up on 6- and 12-month continuous smoking abstinence in patients with atherosclerotic vascular disease.</p><p><strong>Design: </strong>Multicentre, randomised, open-label, blinded-end-point trial with 1:1 randomisation.</p><p><strong>Setting: </strong>Three secondary care hospitals in Norway, with recruitment from November 2021 to October 2023.</p><p><strong>Participants: </strong>Hospitalised patients with established atherosclerotic vascular disease who smoked ≥1 cigarette daily prior to unplanned or elective hospitalisation. A total of 221 were randomised (40% women, mean age 65.2 years), of whom 213 were included in the primary analysis due to 7 deaths and 1 withdrawal.</p><p><strong>Intervention and comparator: </strong>In the intervention group (n = 109), a trained nurse conducted a single 30-minute motivational interviewing-based counselling session, provided a leaflet explaining the local community-based cessation programme, sent discharge information to the general practitioner and arranged for a personal telephone invitation from the centre staff to the follow-up programme. In the control group (n = 111), a physician gave brief cessation advice and the nurse provided a leaflet about the cessation programme and sent discharge information to the general practitioner.</p><p><strong>Measurements: </strong>The primary outcome was self-reported continuous smoking abstinence at 6 months. Secondary outcomes included biochemically validated abstinence (measurement of exhaled carbon monoxide) at 6 months and self-reported abstinence at 12 months. Exploratory outcomes included recurrent vascular events over a median 18-month follow-up.</p><p><strong>Findings: </strong>Smoking abstinence at 6 months was 49.5% (53/107) and 24.5% (26/106) in the intervention and control groups, respectively [odds ratio (OR) = 3.08, 95% confidence interval (CI) = 1.70-5.55, P < 0.001]. The number needed to treat to achieve one additional abstinence was 4 (95% CI = 3-9). Biochemically validated abstinence was 44.9% (48/107) and 20.8% (22/106) in the intervention and control groups, respectively (OR = 3.28, 95% CI = 1.76-6.12). At 12 months, smoking abstinence was 45.7% (48/105) and 27.5% (28/102) in the intervention and control groups, respectively (OR = 2.31, 95% CI = 1.27-4.20). After a median of 18-month follow-up, a prespecified vascular event occurred in 24.8% (27/109) and 34.2% (38/111) of intervention and control participants, respectively.</p><p><strong>Conclusions: </strong>In-hospital motivational counselling combined with proactive referral to follow-up in a community-based cessation programme approximately doubled long-term smok
{"title":"Motivational smoking cessation counselling and community-based follow-up after hospitalisation for vascular disease: A randomised controlled trial.","authors":"Karin Pleym, Elise Sverre, Harald Weedon-Fekjær, Mohpal Singh Kahlon, Marie Stugaard, Einar Husebye, Serena Tonstad, Toril Dammen, John Munkhaugen","doi":"10.1111/add.70249","DOIUrl":"10.1111/add.70249","url":null,"abstract":"<p><strong>Background and aims: </strong>Evidence for motivational interviewing for smoking cessation is weak, with limited data on long-term abstinence rates. This trial aimed to evaluate the effect of in-hospital motivational interviewing-based smoking cessation counselling combined with proactive referral to community-based follow-up on 6- and 12-month continuous smoking abstinence in patients with atherosclerotic vascular disease.</p><p><strong>Design: </strong>Multicentre, randomised, open-label, blinded-end-point trial with 1:1 randomisation.</p><p><strong>Setting: </strong>Three secondary care hospitals in Norway, with recruitment from November 2021 to October 2023.</p><p><strong>Participants: </strong>Hospitalised patients with established atherosclerotic vascular disease who smoked ≥1 cigarette daily prior to unplanned or elective hospitalisation. A total of 221 were randomised (40% women, mean age 65.2 years), of whom 213 were included in the primary analysis due to 7 deaths and 1 withdrawal.</p><p><strong>Intervention and comparator: </strong>In the intervention group (n = 109), a trained nurse conducted a single 30-minute motivational interviewing-based counselling session, provided a leaflet explaining the local community-based cessation programme, sent discharge information to the general practitioner and arranged for a personal telephone invitation from the centre staff to the follow-up programme. In the control group (n = 111), a physician gave brief cessation advice and the nurse provided a leaflet about the cessation programme and sent discharge information to the general practitioner.</p><p><strong>Measurements: </strong>The primary outcome was self-reported continuous smoking abstinence at 6 months. Secondary outcomes included biochemically validated abstinence (measurement of exhaled carbon monoxide) at 6 months and self-reported abstinence at 12 months. Exploratory outcomes included recurrent vascular events over a median 18-month follow-up.</p><p><strong>Findings: </strong>Smoking abstinence at 6 months was 49.5% (53/107) and 24.5% (26/106) in the intervention and control groups, respectively [odds ratio (OR) = 3.08, 95% confidence interval (CI) = 1.70-5.55, P < 0.001]. The number needed to treat to achieve one additional abstinence was 4 (95% CI = 3-9). Biochemically validated abstinence was 44.9% (48/107) and 20.8% (22/106) in the intervention and control groups, respectively (OR = 3.28, 95% CI = 1.76-6.12). At 12 months, smoking abstinence was 45.7% (48/105) and 27.5% (28/102) in the intervention and control groups, respectively (OR = 2.31, 95% CI = 1.27-4.20). After a median of 18-month follow-up, a prespecified vascular event occurred in 24.8% (27/109) and 34.2% (38/111) of intervention and control participants, respectively.</p><p><strong>Conclusions: </strong>In-hospital motivational counselling combined with proactive referral to follow-up in a community-based cessation programme approximately doubled long-term smok","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":"957-969"},"PeriodicalIF":5.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12980294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145562061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-04-01Epub Date: 2025-12-21DOI: 10.1111/pce.70334
Hirotsuna Yamada, Clément E Gille, Pallavi, Li Yan, Gareth Nealon, Jun Wasaki, Erik J Veneklaas, Hans Lambers
Most Proteaceae and some Fabaceae species produce specialised cluster roots (CRs), and are abundant in severely phosphorus (P)-impoverished soils in southwest Australia. Two types of CRs, compound and simple, have been identified. However, the difference in their P-mining strategies remains unclear. Therefore, we conducted glasshouse and field experiments to compare the P-acquisition strategies among 18 CR-producing species in Proteaceae and Fabaceae. Proteaceae produced a significantly larger mass of CRs than Fabaceae. Particularly, Banksia species produced the largest mass of compound CRs and exhibited the greatest net plant-absorbed P in pots and consistently higher mature leaf manganese concentration in the field. In contrast, Hakea and Grevillea species produced less mass of simple CRs but three times as much soil adhered to their CRs per CR dry weight, resulting in greater absorbed P per CR weight. All plants depleted similar P compounds from soil and accessed c. 52% of P that was not extracted by a NaOH-EDTA solution, suggesting that both CRs shared a common physiological function for mining scarcely available P. This study highlights two divergent P-acquisition strategies: greater biomass investment in compound CRs versus greater P-acquisition efficiency in simple CRs.
{"title":"Divergent Phosphorus-Mining Strategies in Simple and Compound Cluster Roots in Extremely Phosphorus-Impoverished Soils in Southwest Australia.","authors":"Hirotsuna Yamada, Clément E Gille, Pallavi, Li Yan, Gareth Nealon, Jun Wasaki, Erik J Veneklaas, Hans Lambers","doi":"10.1111/pce.70334","DOIUrl":"10.1111/pce.70334","url":null,"abstract":"<p><p>Most Proteaceae and some Fabaceae species produce specialised cluster roots (CRs), and are abundant in severely phosphorus (P)-impoverished soils in southwest Australia. Two types of CRs, compound and simple, have been identified. However, the difference in their P-mining strategies remains unclear. Therefore, we conducted glasshouse and field experiments to compare the P-acquisition strategies among 18 CR-producing species in Proteaceae and Fabaceae. Proteaceae produced a significantly larger mass of CRs than Fabaceae. Particularly, Banksia species produced the largest mass of compound CRs and exhibited the greatest net plant-absorbed P in pots and consistently higher mature leaf manganese concentration in the field. In contrast, Hakea and Grevillea species produced less mass of simple CRs but three times as much soil adhered to their CRs per CR dry weight, resulting in greater absorbed P per CR weight. All plants depleted similar P compounds from soil and accessed c. 52% of P that was not extracted by a NaOH-EDTA solution, suggesting that both CRs shared a common physiological function for mining scarcely available P. This study highlights two divergent P-acquisition strategies: greater biomass investment in compound CRs versus greater P-acquisition efficiency in simple CRs.</p>","PeriodicalId":222,"journal":{"name":"Plant, Cell & Environment","volume":" ","pages":"1833-1847"},"PeriodicalIF":6.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12976584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145802787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-04-01Epub Date: 2026-01-11DOI: 10.1111/pce.70375
Jo-Wei Allison Hsieh, Fu-Hui Wu, Dian-Xuan Yang, Ai-En Wu, Ching-Ann Liu, Chang-Hung Chen, Shinn-Zong Lin, Ying-Chung Jimmy Lin, Choun-Sea Lin
Protoplast-based systems provide a powerful and versatile platform for exploring how plants sense and respond to their environment. By enabling the direct delivery of proteins, DNA, and RNA into plant cells after cell wall removal, this approach facilitates precise molecular dissection of signaling, stress adaptation, and gene regulation across both model species and economically important crops. In this review, we analyzed 1050 published articles and categorizing them by delivery methods, research focus, plant species, and tissue types. We further highlight recent advances, including the application of single-cell transcriptomics, which provides unprecedented resolution for dissecting cellular responses and offers deeper insights into the mechanisms underlying stress resilience. Importantly, protoplast regeneration is gaining renewed attention not only as a model system for studying cellular reprogramming but also as a practical platform for crop improvement. Applications of protoplast regeneration include protoplast fusion, which integrates nuclear and organellar DNA/genomes from divergent parents to accelerate breeding and enhance tolerance to both biotic and abiotic stresses. Another important application is CRISPR/Cas ribonucleoprotein (RNP)-based editing targeting stress-resilience-related genes. In asexually propagated or highly heterozygous perennial crops with limited sexual reproduction, protoplast-based RNP delivery offers a viable and regulation-compliant strategy. This approach may help address public concerns over transgenic technologies while enabling the rapid development of stress-tolerant cultivars.
{"title":"Protoplast-Based Functional Genomics and Genome Editing: Progress, Challenges and Applications.","authors":"Jo-Wei Allison Hsieh, Fu-Hui Wu, Dian-Xuan Yang, Ai-En Wu, Ching-Ann Liu, Chang-Hung Chen, Shinn-Zong Lin, Ying-Chung Jimmy Lin, Choun-Sea Lin","doi":"10.1111/pce.70375","DOIUrl":"10.1111/pce.70375","url":null,"abstract":"<p><p>Protoplast-based systems provide a powerful and versatile platform for exploring how plants sense and respond to their environment. By enabling the direct delivery of proteins, DNA, and RNA into plant cells after cell wall removal, this approach facilitates precise molecular dissection of signaling, stress adaptation, and gene regulation across both model species and economically important crops. In this review, we analyzed 1050 published articles and categorizing them by delivery methods, research focus, plant species, and tissue types. We further highlight recent advances, including the application of single-cell transcriptomics, which provides unprecedented resolution for dissecting cellular responses and offers deeper insights into the mechanisms underlying stress resilience. Importantly, protoplast regeneration is gaining renewed attention not only as a model system for studying cellular reprogramming but also as a practical platform for crop improvement. Applications of protoplast regeneration include protoplast fusion, which integrates nuclear and organellar DNA/genomes from divergent parents to accelerate breeding and enhance tolerance to both biotic and abiotic stresses. Another important application is CRISPR/Cas ribonucleoprotein (RNP)-based editing targeting stress-resilience-related genes. In asexually propagated or highly heterozygous perennial crops with limited sexual reproduction, protoplast-based RNP delivery offers a viable and regulation-compliant strategy. This approach may help address public concerns over transgenic technologies while enabling the rapid development of stress-tolerant cultivars.</p>","PeriodicalId":222,"journal":{"name":"Plant, Cell & Environment","volume":" ","pages":"2183-2199"},"PeriodicalIF":6.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12976588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145950915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}